Pendulum Therapeutics latest innovation comes in the form of a GLP-1 probiotic, acting as an appetite suppressor and healthy ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

As pharma giants Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are raking in the cash from their weight loss and ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter.

Eli Lilly’s performance is riding on the success of GLP-1 weight loss and Alzheimer’s treatments. It is especially true for its GLP-1 drugs, which have led to massive gains, with more to come.

But in the last few years, with the approval of GLP-1 drugs like Wegovy and Zepbound, more and more people are opting for obesity medicines over gold-standard surgical treatments. “On a ...

If employees are asking about GLP-1 coverage — in pursuit of general weight loss, not just to treat diabetes — HR may need a plan. At a recent Digital Health New York session titled “The ...